gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Trastuzumab binds HER2 on tumor cells; its Fc engages CD16a on NK cells to mediate ADCC against HER2+ cells. CD16a-expressing cells are effectors, not killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated engagement to trigger ADCC on NK cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06886659
disease_id_num_tar_ref
1015
drug_id_num_tar_ref
2773